tiprankstipranks
Trending News
More News >
Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
Japanese Market
Advertisement

Shin Nippon Biomedical Laboratories, Ltd. (2395) Financial Statements

Compare
2 Followers

Shin Nippon Biomedical Laboratories, Ltd. Financial Overview

Shin Nippon Biomedical Laboratories, Ltd.'s market cap is currently ¥58.70B. The company's EPS TTM is ¥41.3; its P/E ratio is 11.92; and it has a dividend yield of 3.55%. Shin Nippon Biomedical Laboratories, Ltd. is scheduled to report earnings on May 8, 2025, and the estimated EPS forecast is ¥―. See an overview of income statement, balance sheet, and cash flow financials.
Mar 25Mar 24Mar 23Mar 22Mar 21
Income Statement
Total Revenue¥ 32.41B¥ 26.45B¥ 25.09B¥ 17.75B¥ 15.11B
Gross Profit¥ 16.57B¥ 14.28B¥ 13.05B¥ 9.69B¥ 7.55B
Operating Income¥ 2.99B¥ 4.16B¥ 5.25B¥ 4.20B¥ 2.53B
EBITDA¥ 8.83B¥ 8.98B¥ 9.49B¥ 9.49B¥ 5.55B
Net Income¥ 4.92B¥ 5.53B¥ 6.06B¥ 7.13B¥ 3.66B
Balance Sheet
Cash & Short-Term Investments¥ 12.03B¥ 10.61B¥ 10.53B¥ 7.00B¥ 7.29B
Total Assets¥ 92.42B¥ 76.30B¥ 57.24B¥ 39.31B¥ 36.97B
Total Debt¥ 34.47B¥ 26.19B¥ 18.76B¥ 9.14B¥ 12.69B
Net Debt¥ 22.44B¥ 15.91B¥ 8.23B¥ 2.51B¥ 5.46B
Total Liabilities¥ 52.33B¥ 42.14B¥ 30.88B¥ 19.59B¥ 21.13B
Stockholders' Equity¥ 40.02B¥ 34.11B¥ 26.21B¥ 19.56B¥ 15.73B
Cash Flow
Free Cash Flow¥ -3.82B¥ -6.50B¥ -951.70M¥ 4.34B¥ 3.63B
Operating Cash Flow¥ 7.04B¥ 2.11B¥ 4.00B¥ 5.95B¥ 4.75B
Investing Cash Flow¥ -11.61B¥ -6.91B¥ -5.93B¥ -4.27B¥ -268.66M
Financing Cash Flow¥ 5.84B¥ 5.32B¥ 6.27B¥ -4.91B¥ -2.47B
Currency in JPY

Shin Nippon Biomedical Laboratories, Ltd. Earnings and Revenue History

Shin Nippon Biomedical Laboratories, Ltd. Debt to Assets

Shin Nippon Biomedical Laboratories, Ltd. Cash Flow

Shin Nippon Biomedical Laboratories, Ltd. Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis